Evaluate the effectiveness of servo-ventilation therapy in patients with co-existing sleep related breathing disorders and heart failure [Evaluation de la BiPAP autoSV Advanced dans le traitement du syndrome dapnées mixtes du sommeil chez les patients ayant une insuffisance cardiaque congestive]
| ISRCTN | ISRCTN26654460 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN26654460 |
| Secondary identifying numbers | EAME09ASV01 |
- Submission date
- 08/04/2010
- Registration date
- 22/04/2010
- Last edited
- 01/03/2011
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Jean-Louis Pepin
Scientific
Scientific
Pôle de Rééducation et Physiologie
Laboratoire dExploration Fonctionnelles Cardio-Respiratoires et Laboratoire du Sommeil
CHU de Grenoble
BP 217
Grenoble
38043
France
Study information
| Study design | Observational longitudinal case-control multicentre study |
|---|---|
| Primary study design | Observational |
| Secondary study design | Case-control study |
| Study setting(s) | Other |
| Study type | Quality of life |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Evaluate the effectiveness of servo-ventilation therapy in patients with co-existing sleep related breathing disorders and heart failure: a 6-month longitudinal case-control observational study |
| Study objectives | Servo-ventilation therapy may improve the quality of life and prognosis in patients with co-existing sleep disordered breathing and heart failure. This is an observational trial where we would like to follow up a group of such patients and to evaluate the outcomes. |
| Ethics approval(s) | Comité de Protection des Personnes Sud Est V approved on the 13th May 2009 (ref: CPP 09-RESP-1) |
| Health condition(s) or problem(s) studied | Sleep related breathing disorders/heart failure |
| Intervention | After checking inclusion/exclusion criterias and having the patient consent signed, the following steps will be as follows: 1. First Visit (V0): 1.1. Polysomnography (PSG) diagnostic night 1.2. Clinical evaluation 1.3. Arterial and blood review 1.4. Cardiac evaluation 1.5. PSG control night 2. Second Visit at 10 days (V1): 2.1. Clinical evaluation 2.2. Blood pressure measurement 2.3. Questionnaires 2.4. Device compliance download 2.5. Polygraphy ambulatory recording 3. Third Visit at 1 month (V2): 3.1. Clinical evaluation 3.2. Blood pressure measurement 3.3. Questionnaires 3.4. Device compliance download 4. Fourth Visit at 3 months (V3): 4.1. Clinical evaluation 4.2. Blood pressure measurement 4.3. Questionnaires 4.4. Device compliance download 4.5. Effort test 4.6. Walking test 4.7. Blood gases/NTProBNP 5. Fifth Visit at 6 months (V4): 5.1. Clinical evaluation 5.2. Blood pressure measurement 5.3. Questionnaires 5.4. Device compliance download 5.5. Scan or isotope imaging 5.6. Effort test 5.7. Measuring the ventilatory response to CO2 5.8. Walking test 5.9. Blood gases/determination of NT-proBNP 5.10. PSG control night |
| Intervention type | Other |
| Primary outcome measure | Assess the correction of the apnoea/hypopnoea index (AHI); the method to evaluate this outcome will be the PSG recording. |
| Secondary outcome measures | 1. Cardiovascular function: assessing long-term changes in left ventricular ejection fraction (LVEF) when using the in BiPAP autoSV Advanced: 1.1. LVEF: assessed by measuring Scan or Isotope imaging 1.2. Left Ventricular Diastolic Function (FDVG) 1.3. Determination of NT-proBNP 2. Improvement of cardiorespiratory function in BiPAP autoSV Advanced: 2.1. Effort Test: measurement of oxygen consumption (VO2max), ventilatory threshold value, ventilatory response to CO2 (VE/VCO2) 2.2. Six-minute walk Test: to assess the distance in meters, heart rate and SaO2 at the end of trial 2.3. PSG: blood average oxygen Saturation (SaO2) and oxygen desaturation index per hour of sleep. The desaturation threshold is set at 3%. In addition, we calculate the time spent with SaO2 <90% 3. Quality of sleep: 3.1. Total time of sleep (in minutes) 3.2. Percentage of REM sleep, slow wave sleep light (I and II), and slow deep (III and IV) 3.3. Index of arousal associated with respiratory events per hour 4. Effectiveness of sleep: ratio of total sleep time and time spent in bed 5. Questionnaires: 5.1. Daytime sleepiness: Epworth Sleepiness Questionnaire (QSE) 5.2. Quality of life Questionnaire Minnesota 6. Acceptance rate expressed by: 6.1. Compliance of more than 4 hours 6.2. Percentage of patients continuing their treatment at 6 months |
| Overall study start date | 10/04/2010 |
| Completion date | 10/04/2011 |
| Reason abandoned (if study stopped) | Participant recruitment issue |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Other |
| Sex | Both |
| Target number of participants | 40 |
| Key inclusion criteria | 1. Patients with heart failure and obstructive/central sleep apnoea (no specific age range or sex) 2. Naive patients to positive airway pressure therapy 3. Apnoea/Hypopnoea Index greater than 30/h with at least 30% of central events 4. Left ventricular ejection fraction less than 45% 5. Patients with a New York Heart Association (NYHA) class between II and IV 6. Stable and optimised medical cardiac therapy since one month at least 7. Informed consent signed |
| Key exclusion criteria | 1. Patients with associated chronic obstructive pulmonary disease 2. Patients with unstable heart failure or stable since less than one month 3. Patients with unstable angina pectoris or stable since less than one month 4. Patients with stroke 5. Patients with ischaemic cardiomyopathy or cardiogenic oedema 6. Patients with a cardiac resynchronisation scheduled within the next 6 months 7. Patients with a valvular surgery scheduled within the next 6 months 8. Patients participating to another clinical trial or not affiliated to the social security system 9. Patients in jail or hospitalised without consent 10. Majors protected by the law or detainees 11. Minors 12. Pregnant or nursing women |
| Date of first enrolment | 10/04/2010 |
| Date of final enrolment | 10/04/2011 |
Locations
Countries of recruitment
- France
Study participating centre
Pôle de Rééducation et Physiologie
Grenoble
38043
France
38043
France
Sponsor information
Phillips Respironics International Inc. (France)
Industry
Industry
2 rue du château de Bel Air
Carquefou
44470
France
| Website | http://www.medical.philips.com/main/homehealth/index.wpd |
|---|---|
"ROR" |
https://ror.org/05jz46060 |
Funders
Funder type
Industry
Phillips Respironics International Inc. (France)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
